Prostate Cancer

Prostate Active Surveillance Study (PASS)
Principal Investigator: Dr. Ian Thompson Jr., MD IRB #: HSC-20080303H
Department Address: MARC, Department of Urology, Ste. 4B, 8300 Floyd Curl Dr., San Antonio, TX 78229

 

Contact Person:

Carol Lizcano, LVN, BS
Office phone: 210-450-0705
Fax: 210-562-9386
lizcanoc@uthscsa.edu

   

Enrollment Notes:  All study visits are completed at the  MARC in conjunction with biannual visits for active surveillance with Chief Investigator

The target age is:
   

Study Begin and End Date: October 2008

Eligibility Criteria:  Participant must have clinically localized prostate cancer that has not been treated.  Participant has elected active surveillance and decided not to undergo surgery, radiation, or other medical treatment for prostate cancer at this time.

 

Type of Study: Observational

 
     
Funding Source: Non-Profit Sponsor – The Canary Foundation
Detailed description of this study

All care participants receive is Standard of Care for Active Surveillance.  Research procedures include blood draw every 6 months for serum and plasma, urine collections, prostate tissue collection, Food & Supplement Use Questionnaire and the Health-Related Quality of Life Questionnaire.  Purpose of the PASS is to understand how prostate cancer behaves and to find unique biomarkers (substances in blood, urine or tissue which can indicate the presence of cancer) associated with prostate cancer.


Open vs. Robotic-Assisted Radical Cystectomy: A Randomized Trial
Dipen J. Parekh, MD IRB #: HSC- 20090150H
Department Address: MARC, Department of Urology, Ste. 4B, 8300 Floyd Curl Dr., San Antonio, TX 78229

 

Contact Person:

Lindsay Brown
210-450-0752
brownls@uthscsa.edu

   

Enrollment Notes:

The target age is:>18 or <99 years
   

Study Begin and End Date: August 2011

Eligibility Criteria:Patient must have biopsy-proven bladder cancer; official pathology report reviewed by PI is required; bladder cancer must be clinical state T1-T4, N0-1, M0 (AJC 7th Edition) or refractory carcinoma in situ (cis).

 

Type of Study: Randomized Study – Open Radical Cystectomy or Robotic-Assisted Radical Cystectomy (RARC)

 
     
Funding Source: National Institutes of Health
Detailed description of this study
Participant having radical cystectomy  and eligible to have either the Open Cystectomy or RARC will be randomized to one of these.  Goal of the research is (1) to learn whether participants undergoing a RARC have fewer cancer-related outcomes compared to open surgery; and (2) to learn if participants undergoing  RARC recover more quickly than or at the same rate as participants undergoing an open cystectomy.  Participant medical records will be reviewed for approximately three years after the surgery to determine these outcomes.  

 


Establishing Community-Based Urinary Biomarkers: A Study on Prostate Screening and Detection
Principal Investigator: Dr. Ian Thompson Jr., MD IRB #: HSC-2002-0380H
Department Address, Main Campus


For more information
click to view video.

Contact Person:

SABOR Team
(210) 567-0214
Mullish@uthscsa.edu

   

Enrollment Notes:  Men only

The target age is:
  No age limitation
   

Study Begin and End Date: September 2002-ongoing

Eligibility Criteria:  Men who have been diagnosed with prostate cancer.

 

Type of Study: Observational

 
     
Funding Source: NCI through the Early Detection Research Network
Detailed description of this study

This research study has been ongoing for 10 years and originally funded by the American Cancer Society.  For the past 3 years it has been funded by the National Cancer institute but with a different focus.  The three goals of this study are:

  1. To improve the accuracy of screening tests for the diagnosis of prostate cancer.
  2. Identify biomarkers that will predict how aggressive prostate cancer will be.  The tests currently in use for screening for prostate cancer are the PSA blood test and digital rectal examination (DRE) of the prostate.  When either or both of these tests are positive, a tissue biopsy of the prostate is recommended.
  3. The third goal is to provide accurate information about how rapidly prostate cancers will become worse.  To accomplish this we will study tissue and blood to identify proteins and genes that are present at high or low levels in prostate cancers that progress slowly versus those that progress more rapidly.

Establishing Community-Based Urinary Biomarkers: A Study on Prostate Screening and Detection
Principal Investigator: Dr. Ian Thompson Jr., MD IRB #: HSC-2011-0312H
Department Address, Main Campus


For more information
click to view video.

Contact Person:

SABOR Team
(210) 567-0214
Longorian2@uthscsa.edu or longj4@uthscsa.edu

   

Enrollment Notes:  Men only

The target age is:
  Men ages 40-79
   

Study Begin and End Date: September 2011-September 2013

Eligibility Criteria:  Men ages 40-79 who are interested in a prostate screening exam and do not have a history of prostate cancer, prostate surgery or a prostate biopsy.  

 

Type of Study: Community Based Screening

 
     
Funding Source: NCI through the Early Detection Research Network
Detailed description of this study

This research study is focused on expanding our knowledge of a biomarker for prostate cancer called PCA3, a molecule found in the prostate gland.  The goal of this study is to evaluate this new biomarker in normal prostate cancer screening.  PSA (prostate specific antigen) screening and a digital rectal exam (DRE), to check for growths or enlargement of the prostate, will be provided at no cost. Participants will be asked to attend 1 visit with physicians and research staff as well as provide annual follow up information over the phone for up to 5 years.  Procedures will take approximately 1 hour and written PSA results will be sent to you, and if you request, to your provider.


San Antonio Center of Biomarkers of Risk for Prostate Cancer
Principal Investigator: Dr. Ian Thompson Jr., MD IRB #: HSC-2000-0030H
Department Address, Main Campus


For more information
click to view video.

Contact Person:

SABOR Team
(210) 567-0214
Longorian2@uthscsa.edu or longj4@uthscsa.edu

   

Enrollment Notes:  Men ages 35 and above

The target age is:
  Recommended age 45
   

Study Begin and End Date: January 2000- ongoing

Eligibility Criteria:  Men ages 35 and above who are interested in PSA screening and have not been diagnosed with prostate cancer.  

 

Type of Study: Screening Cohort

 
     
Funding Source: NCI through the Early Detection Research Network
Detailed description of this study

The San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR), is a long-term research study of a large group of men that will help researchers improve the detection of prostate cancer.  The program provides annual PSA (Prostate Specific Antigen) screening at no cost.  Subjects participating in this study will be asked to attend one visit per year for PSA screening and complete annual follow-up phone interviews. Written PSA results will be provided to you, and if you request, to your provider.  


Improving Prostate Biopsy Efficiency: The Finasteride Challenge
Chief investigator: Dr. Ian Thompson, MD IRB #: HSC-2010-0352H
Department of Urology, 7703 Floyd Curl Drive, San Antonio, TX 78229


For more information
click to view video.

You may contact Antonio Gutierrez, MS at 210-567-1995 or gutierreza9@uthscsa.edu
    Only male subjects are needed for this study.
The target age is:
  55 years and older
    This study begins 2/1/2011 and is scheduled to end 9/30/2015

Eligibility Criteria: Men at risk of prostate cancer who are considering a prostate biopsy with an elevated PSA.

 
The type of this study is:  
  Intervention Study  
Funding Source: National Institutes of Health (NIH)
Detailed description of this study
Randomized, Placebo-controlled, Double Blind study to improve prostate cancer screening with PSA using a 3-month treatment of Finasteride vs. placebo

Identification of Protein and Genetic Biomarkers of Prostate Cancer and Risk Factors for Progression of Disease
Chief investigator: Dr. Ian Thompson, MD IRB #: HSC-20020-380H
Department of Urology, 7703 Floyd Curl Drive, San Antonio, TX 78229


For more information
click to view video.

You may contact Brandi Weaver at 210-567-0178 or weaverb@uthscsa.edu
    Only male subjects are needed for this study.
The target age is:
  19 - 64 years
  64 years and older
    This study is in progress and has no scheduled date of completion.
Eligibility Criteria: For men with a previous diagnosis of prostate cancer.  
Funding Source: National Cancer Institute
Detailed description of this study
The purpose of this study is to identify genetic variants that predict progression of prostate cancer.

CFG920

Description:

CFG920 is a non-steroidal, reversible dual inhibitor of CYP17 and CYP11B2 with potential antiandrogen and antineoplastic activities. In this Phase I/II study CFG920 will be administered orally in patients with metastatic castration-resistant prostate cancer after progressing (or have refused) on Abiraterone and Docetaxel.


Type(s) of Cancer: Prostate Cancer
Study Phase(s): Phase I
Phase II
Contact: Epp Goodwin at (210) 450-5798

Metformin

Description:

Metformin is widely used anti-diabetic medicine. It can also act as an anti-cancer agent by activation of AMP-activated protein kinase (AMPK) pathway and subsequent inhibition of mTOR that blocks the cancer cell growth and proliferation. It may also lessen the symptoms of metabolic syndrome caused by androgen deprivation therapy. In this Phase II study patients with advanced prostate cancer will be randomly selected to receive castration only or castration plus metformin as first line treatment.


Type(s) of Cancer: Prostate Cancer
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798

Nexrutine in Prostrate Cancer Patients Undergoing Surgery or Radiation Therapy (only open to veterans)

Description:

For veterans only; Patients will take Nexrutine® (an oral dietary supplement) prior to and during radiation treatment for prostate cancer or prior to surgery for prostate cancer. The purpose of the study is to see whether taking Nexrutine® will cause the PSA (Prostate Specific Antigen) to decline.


Type(s) of Cancer: Prostate Cancer
Study Phase(s): Phase II
Contact: Carol Jenkins at (210) 450-5924